FDA Approved Indications for this Orphan Drug:

Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

FDA Marketing Approval issued as of:
06/11/1996

Orphan Drug exclusivity ends on:
06/11/2003
Company Making and Marketing this drug:
Amedra Pharmaceuticals LLC

FDA Designation Date:
1/18/96

FDA Drug Designation:
Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.